Therapeutic drug monitoring as a tool in treating HIV infection
- 1 January 2001
- journal article
- review article
- Published by Wolters Kluwer Health in AIDS
- Vol. 15, S171-S181
- https://doi.org/10.1097/00002030-200100005-00021
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Interactions among Drugs for HIV and Opportunistic InfectionsNew England Journal of Medicine, 2001
- An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancyAIDS, 2001
- Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus‐infected patients with chronic liver diseaseBritish Journal of Clinical Pharmacology, 2000
- Pharmacodynamics of Human Immunodeficiency Virus Type 1 Protease InhibitorsClinical Infectious Diseases, 2000
- Antiviral Effect and Pharmacokinetic Interaction between Nevirapine and Indinavir in Persons Infected with Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 1999
- Relationships Between Exposure to Saquinavir Monotherapy and Antiviral Response in HIV-Positive PatientsClinical Pharmacokinetics, 1999
- Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavirAIDS, 1997
- Improved tolerability of ritonavir derived from pharmacokinetic principlesBritish Journal of Clinical Pharmacology, 1996
- RitonavirDrugs, 1996
- A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)AIDS, 1996